Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator

被引:2
|
作者
Karnam, Ravikiran S. S. [1 ,2 ]
Punchhi, Gopika [1 ,3 ]
Mitsakakis, Nicholas [4 ]
Chen, Shiyi [5 ]
Saracino, Giovanna [6 ]
Lilly, Leslie [1 ,7 ,8 ]
Asrani, Sumeet K. K. [6 ]
Bhat, Mamatha [1 ,7 ,8 ,9 ]
机构
[1] Univ Hlth Network, Ajmera Transplant Program, Toronto, ON, Canada
[2] Narayana Hlth, Bengaluru, India
[3] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[4] Eastern Ontario Res Inst, Childrens Hosp, Ottawa, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Biostat Dept, Toronto, ON, Canada
[6] Baylor Univ, Med Ctr, Dallas, TX USA
[7] Univ Toronto, Dept Med, Div Gastroenterol, Toronto, ON, Canada
[8] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
[9] Univ Toronto, Dept Med, 585 Univ Ave, Toronto, ON, Canada
关键词
liver transplantation; NASH; outcomes; recipient factors; risk score; risk stratification; CRYPTOGENIC CIRRHOSIS; SURVIVAL; DISEASE; MODEL; SCORE; MELD; MORTALITY; UTILITY;
D O I
10.1111/ctr.14930
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundNon-alcoholic Steatohepatitis (NASH) cirrhosis is the second most common indication for liver transplantation (LT) in the US and often is associated with significant co-morbidities. We validated a model and risk prediction score that reflects the benefit derived from LT for NASH cirrhosis by predicting 5-year survival post-LT. MethodsWe developed a prediction score utilizing 6515 NASH deceased donor LT (DDLT) recipients from 2002 to 2019 from the Scientific Registry of Transplant Recipients (SRTR) database to identify a parsimonious set of independent predictors of survival. Coefficients of relevant recipient factors were converted to weighted points to construct a risk scoring system that was then externally validated. ResultsThe final risk score includes the following independent recipient predictors and corresponding points: recipient age (5 points for age >= 70 years), functional status (3 points for total assistance), presence of TIPSS (2 points), hepatic encephalopathy (1 point), serum creatinine (5 points if >1.45 mg/dl), need for mechanical ventilation (3 points), and dialysis within 1 week prior to LT (7 points). Diabetes is a stratifying variable for baseline risk. Scores range from 0 to 20 with scores above 13 having an overall survival of <65% at 5 years post-LT. Internal and external validation indicated good predictive ability. ConclusionOur practically useable and validated risk score helps to identify and stratify candidates who will derive the most long-term benefit from LT for NASH cirrhosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Recurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Following Liver Transplantation for NASH Cirrhosis
    Matsuoka, Lea
    Slaughter, James
    Campbell, Kathyrn
    Kerr, Ashlie
    Hamel, Stephanie
    Garza, Carissa
    Chotai, Pranit
    Alexopoulos, Sophoclis
    Scanga, Andrew
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 15 - 15
  • [2] Non-alcoholic fatty liver disease (NAFLD) after orthotopic liver transplantation (OLT) in patients with cryptogenic cirrhosis (CC) and non-alcoholic steatohepatitis (NASH)
    Amaro, R
    Montalbano, M
    Acosta, RC
    Concha, R
    Weppler, D
    Neff, GW
    O'Brien, CB
    Molina, EG
    Schiff, ER
    Tzakis, AG
    GASTROENTEROLOGY, 2001, 120 (05) : A118 - A118
  • [3] LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) COMPARED TO NON-NASH PATIENTS
    Sadler, Erin
    Mehta, Neil
    Bhat, Mamatha
    Ghanekar, Anand
    Greig, Paul
    Grant, David
    Yao, Francis
    Sapisochin, Gonzalo
    TRANSPLANT INTERNATIONAL, 2017, 30 : 93 - 93
  • [4] Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis
    Castello, Beatriz
    Aguilera, Victoria
    Teresa Blazquez, M.
    Rubin, Angel
    Garcia, Maria
    Vinaixa, Carmen
    Benlloch, Salvador
    SanJuan, Fernando
    Montalva, Eva
    Lopez, Rafael
    Berenguer, Marina
    ANNALS OF HEPATOLOGY, 2019, 18 (06) : 855 - 861
  • [5] Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
    Tasneem, Abbas Ali
    Luck, Nasir Hassan
    Majid, Zain
    TROPICAL DOCTOR, 2018, 48 (02) : 107 - 112
  • [6] Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis
    Newsome, Philip Noel
    Allison, M. E.
    Andrews, P. A.
    Auzinger, G.
    Day, C. P.
    Ferguson, J. W.
    Henriksen, P. A.
    Hubscher, S. G.
    Manley, H.
    McKiernan, P. J.
    Millson, C.
    Mirza, D.
    Neuberger, J. M.
    Oben, J.
    Pollard, S.
    Simpson, K. J.
    Thorburn, D.
    Tomlinson, J. W.
    Wyatt, J. S.
    GUT, 2012, 61 (04) : 484 - 500
  • [7] Non-alcoholic steatohepatitis and liver transplantation
    Gitto, Stefano
    Vukotic, Ranka
    Vitale, Giovanni
    Pirillo, Martina
    Villa, Erica
    Andreone, Pietro
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 587 - 591
  • [8] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
  • [9] Liver cirrhosis and hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
    Hashimoto, Etsuko
    Yatsuji, Satoru
    Shiratori, Keiko
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A65 - A65
  • [10] NASH, acute Liver Failure and Comlications of Liver Cirrhosis Non-Alcoholic Steatohepatitis (NASH) - of the Pathophysiology of innovative Treatment
    Tilg, Herbert
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (11): : 713 - 714